Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33525545 | 0.91 | HPGD (0.43) | HSD17B10HPGDOPRK1NPC1SMN1; SMN2 | |
| SCHEMBL33525876 | 0.88 | HSD17B10 (0.41) | HSD17B10HPGDOPRK1NPC1SMN1; SMN2 | |
| SCHEMBL12716281 | 0.81 | HSD17B10 (0.51) | HSD17B10HPGDNPC1ALDH1A1LMNA | |
| SCHEMBL17664708 | 0.81 | HSD17B10 (0.51) | HSD17B10HPGDNPC1ALDH1A1LMNA | |
| SCHEMBL20281885 | 0.81 | HSD17B10 (0.46) | HSD17B10HPGDNPC1ALDH1A1LMNA | |
| SCHEMBL12524284 | 0.81 | HSD17B10 (0.46) | HSD17B10HPGDNPC1ALDH1A1LMNA | |
| SCHEMBL27158844 | 0.81 | HSD17B10 (0.46) | HSD17B10HPGDNPC1ALDH1A1LMNA | |
| SCHEMBL14664469 | 0.80 | HSD17B10 (0.47) | HSD17B10HPGDNPC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL31085807 | 0.79 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1NPC1SMN1; SMN2 | |
| SCHEMBL31085624 | 0.79 | HSD17B10 (0.36) | HSD17B10HPGDOPRK1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| CN-114901652-A | Substituted saturated and unsaturated N-heterocyclic carboxamides and related compounds for the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | HSD17B10 966/4885HPGD 213/4885OPRK1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.